emb-06
mAbexperimentalBi-specific
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 20, 2021 (NCT04735575)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068226 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07236411 | Phase 1 | Dec 15, 2025 | Candid Therapeutics |
| NCT07215650 | Phase 1 | Sep 16, 2025 | Candid Therapeutics |
| NCT07215663 | Phase 1 | Sep 4, 2025 | Candid Therapeutics |
| NCT07158996 | Early Phase 1 (Phase 1) | Sep 4, 2025 | Jiao Tong University |
| NCT07135219 | Early Phase 1 (Phase 1) | Jul 16, 2025 | Peking University |
| NCT06946199 | Phase 1 | Jun 1, 2025 | Huazhong University of Science and Technology |
| NCT04735575 | Phase 1/Phase 2 (Phase 2) | May 20, 2021 | Shanghai EpimAb Biotherapeutics Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Candid Therapeutics | For profit | 3 | 3 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shanghai EpimAb Biotherapeutics Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1